Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Ji-Won | - |
dc.contributor.author | Kim, Myeong Gyu | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Koh, Youngil | - |
dc.contributor.author | Kwon, Ji-Hyun | - |
dc.contributor.author | Kim, Inho | - |
dc.contributor.author | Park, Seonyang | - |
dc.contributor.author | Kim, Byoung Kook | - |
dc.contributor.author | Oh, Jung Mi | - |
dc.contributor.author | Kim, Kyung Im | - |
dc.contributor.author | Yoon, Sung-Soo | - |
dc.date.accessioned | 2021-09-03T11:06:04Z | - |
dc.date.available | 2021-09-03T11:06:04Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01-03 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84949 | - |
dc.description.abstract | The aim of this study was to evaluate the efficacy and safety of recombinant human epidermal growth factor (rhEGF) oral spray for oral mucositis (OM) induced by intensive chemotherapy with hematopoietic stem cell transplantation. In this phase 2 study, patients were randomized to either rhEGF (50 microg/ mL) or placebo in a 1:1 ratio. The primary endpoint was incidence of National Cancer Institute (NCI) grade >= 2 OM. A total of 138 patients were enrolled in this study. In the intention-to-treat analysis, rhEGF did not reduce the incidence of NCI grade >= 2 OM (p = 0.717) nor reduce its duration (p = 0.725). Secondary endpoints including the day of onset and duration of NCI grade >= 2 OM, the incidence of NCI grade >= 3 OM and its duration, and patient-reported quality of life were also similar between the two groups. In the per-protocol analysis, however, the duration of opioid analgesic use was shorter in the rhEGF group (p = 0.036), and recipients in the rhEGF group required a lower cumulative dose of opioid analgesics than those in the placebo group (p = 0.046), among patients with NCI grade >= 2 OM. Adverse events were mild and transient. This study found no evidence to suggest that rhEGF oral spray reduces the incidence of OM. However, further studies are needed to investigate the effect of rhEGF on OM-induced pain reduction after intensive chemotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PUBLIC LIBRARY SCIENCE | - |
dc.subject | ECONOMIC OUTCOMES | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | PALIFERMIN | - |
dc.subject | THERAPY | - |
dc.subject | CANCER | - |
dc.subject | HEAD | - |
dc.title | Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Kyung Im | - |
dc.identifier.doi | 10.1371/journal.pone.0168854 | - |
dc.identifier.scopusid | 2-s2.0-85008352212 | - |
dc.identifier.wosid | 000391612300060 | - |
dc.identifier.bibliographicCitation | PLOS ONE, v.12, no.1 | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.citation.title | PLOS ONE | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.subject.keywordPlus | ECONOMIC OUTCOMES | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | PALIFERMIN | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | HEAD | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.